Both of these drugs contain the same strengths of two female hormones: ethinyl estradiol an estrogen and desogestrel a progestin. These hormones help prevent pregnancy in two ways.
One, they stop you from ovulating releasing an egg from your ovary. Two, they cause changes in your cervix and uterus that make it harder for you to get pregnant. Azurette and Kariva do not protect you against infection with HIV or other sexually transmitted diseases.
Azurette and Kariva are tablets that you take by mouth. They come in blister packs with 28 tablets per pack. In each pack, 26 tablets contain hormones, and the other two do not. For each cycle, you would take:. Insurance companies are more likely to cover generics than brand-name drugs because generics are cheaper. That means Azurette and Kariva are more likely to be covered than the brand-name version, Mircette. Also, the cash price what you would pay without insurance for generic drugs may be less than for brand-name drugs.
With or without insurance, both Azurette and Kariva would likely be cheaper than Mircette. All drugs can cause side effects. Some effects are more common and may go away after a few days.
Others are more serious. These side effects can require medical care. Azurette, Kariva, and all other birth control pills have similar common side effects.
These include:. Azurette and Kariva have similar serious side effects. These side effects are rare in healthy women. They include:. An interaction is when a substance changes the way a drug works.
An interaction can harm you or prevent the drug from working well. Certain drugs may interact with Azurette and Kariva and other birth control pills. Oral contraceptives come in many different brands. Different brands of oral contraceptives contain slightly different medications or doses, are taken in slightly different ways, and have different risks and benefits.
Be sure that you know which brand of oral contraceptives you are using and exactly how you should use it. Ask your doctor or pharmacist for a copy of the manufacturer's information for the patient and read it carefully. If you have a tablet packet, take 1 tablet daily for 21 days and then none for 7 days.
Then start a new packet. If you have a tablet packet, take 1 tablet daily for 28 days in a row in the order specified in your packet. Start a new packet the day after you take your 28th tablet. The tablets in most tablet packets may have different colors. Many tablet packets have certain color tablets that contain different amounts of estrogen and progestin, but also may have other color tablets which contain an inactive ingredient or a folate supplement.
If you have a day tablet packet, take 1 tablet daily for 91 days. Your packet will contain three trays of tablets. Start with the first tablet on the first tray and continue taking 1 tablet every day in the order specified on the packet until you have taken all of the tablets on all of the trays. The last set of tablets are a different color. These tablets may contain an inactive ingredient, or they may contain a very low dose of estrogen. Start your new packet the day after you take your 91st tablet.
Your doctor will tell you when you should start taking your oral contraceptive. Oral contraceptives are usually started on the first or fifth day of your menstrual period or on the first Sunday after or on which bleeding begins.
Your doctor will also tell you whether you need to use another method of birth control during the first 7 to 9 days that you take your oral contraceptive and will help you choose a method.
Follow these directions carefully. You will probably experience withdrawal bleeding similar to a menstrual period while you are taking the inactive tablets or the low dose estrogen tablets or during the week that you do not take your oral contraceptive.
If you are taking the type of packet that only contains active tablets, you will not experience any scheduled bleeding, but you may experience unexpected bleeding and spotting, especially at the beginning of your treatment. Be sure to start taking your new packet on schedule even if you are still bleeding. You may need to use a backup method of birth control if you vomit or have diarrhea while you are taking an oral contraceptive.
Talk to your doctor about this before you begin to take your oral contraceptive so that you can prepare a backup method of birth control in case it is needed. If you vomit or have diarrhea while you are taking an oral contraceptive, call your doctor to find out how long you should use the backup method.
If you have recently given birth, wait until 4 weeks after delivery to begin taking oral contraceptives. If you have had an abortion or miscarriage, talk to your doctor about when you should begin taking oral contraceptives. Oral contraceptives will work only as long as they are taken regularly. Continue to take oral contraceptives every day even if you are spotting or bleeding, have an upset stomach, or do not think that you are likely to become pregnant.
Do not stop taking oral contraceptives without talking to your doctor. Oral contraceptives are also sometimes used to treat heavy or irregular menstruation and endometriosis a condition in which the type of tissue that lines the uterus [womb] grows in other areas of the body and causes pain, heavy or irregular menstruation [periods], and other symptoms. Talk to your doctor about the risks of using this medication for your condition.
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. If you miss doses of your oral contraceptive, you may not be protected from pregnancy.
You may need to use a backup method of birth control for 7 to 9 days or until the end of the cycle. Every brand of oral contraceptives comes with specific directions to follow if you miss one or more doses. Carefully read the directions in the manufacturer's information for the patient that came with your oral contraceptive.
If you have any questions, call your doctor or pharmacist. Continue to take your tablets as scheduled and use a backup method of birth control until your questions are answered. Oral contraceptives may increase the chance that you will develop liver tumors. These tumors are not a form of cancer, but they can break and cause serious bleeding inside the body.
Oral contraceptives and death from myocardial infarction. Br Med J ; 2 — Myocardial infarction in young women with special reference to oral contraceptive practice. Lancet ; — Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. Vessey MP. Female hormones and vascular disease—an epidemiological overview.
Br J Fam Plann ; — Cardiovascular risk status and oral contraceptive use, United States, — Prevent Med ; — The relative impact of smoking and oral contraceptive use on women in the United States.
JAMA ; — Layde PM, Beral V. Table 5 Lancet ; — Knopp RH. Arteriosclerosis risk: the roles of oral contraceptives and postmenopausal estrogens. J Reprod Med ; 31 9 Supplement — Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: Differential changes in high-density lipoproteins subclasses.
Am J Obstet ; — Wynn V, Niththyananthan R. The effect of progestin in combined oral contraceptives on serum lipids with special reference to high-density lipoproteins. Am J Obstet Gynecol ; — Wynn V, Godsland I. Effects of oral contraceptives and carbohydrate metabolism.
LaRosa JC. Atherosclerotic risk factors in cardiovascular disease. Investigation of death from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age.
Increased risk of thrombosis due to oral contraceptives: a further report. Am J Epidemiol ; 2 — Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. Vessey MP, Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. A further report. Oral contraceptives and non-fatal vascular disease—recent experience. Obstet Gynecol ; 59 3 — A long-term follow-up study of women using different methods of contraception: an interim report.
Biosocial Sci ; — Royal College of General Practitioners: Oral contraceptives, venous thrombosis, and varicose veins. J Royal Coll Gen Pract ; — Collaborative Group for the Study of Stroke in Young Women: Oral contraception and increased risk of cerebral ischemia or thrombosis. Petitti DB, Wingerd J. Use of oral contraceptives, cigarette smoking, and risk of subarachnoid hemorrhage. Inman WH.
Oral contraceptives and fatal subarachnoid hemorrhage. Collaborative Group for the Study of Stroke in Young Women: Oral contraceptives and stroke in young women: associated risk factors.
Thromboembolic disease and the steroidal content of oral contraceptives. A report to the Committee on Safety of Drugs. Br Med J ; — Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of and mcg oestrogen preparations.
Kay CR. Royal College of General Practitioners: Incidence of arterial disease among oral contraceptive users. Ory HW. Mortality associated with fertility and fertility control: Family Planning Perspectives ; — Breast cancer risk in young women and use of oral contraceptives: possible modifying effect of formulation and age at use.
Oral contraceptives and breast cancer: A national study. Breast cancer risk in relation to early oral contraceptive use. Obstet Gynecol ; — Oral contraceptive use and breast cancer in young women in Sweden letter.
Early contraceptive use and breast cancer: Results of another case-control study. Br J Cancer ; — Oral contraceptives and neoplasia: update. Fertil Steril ; — The pill and breast cancer: why the uncertainty? Shapiro S. Oral contraceptives—time to take stock. Contraceptive choice and prevalence of cervical dysplasia and carcinoma in situ. Neoplasia of the cervix uteri and contraception: a possible adverse effect of the pill.
Lancet ; Long-term use of oral contraceptives and risk of invasive cervical cancer. Int J Cancer ; — Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. Recurrent massive hemorrhage from benign hepatic tumors secondary to oral contraceptives. Br J Surg ; — Klatskin G. Hepatic tumors: possible relationship to use of oral contraceptives. Gastroenterology ; — Hepatocellular carcinoma and oral contraceptives. Oral contraceptives and hepatocellular carcinoma. Cancer of the liver and oral contraceptives.
Harlap S, Eldor J. Births following oral contraceptive failures. Teratogenic hazards of oral contraceptives analyzed in a national malformation register.
Oral contraceptives and birth defects. Am J Epidemiol ; — Maternal hormone therapy and congenital heart disease. Teratology ; — Exogenous hormones and other drug exposures of children with congenital heart disease. Boston Collaborative Drug Surveillance Program: Oral contraceptives and venous thromboembolic disease, surgically confirmed gallbladder disease, and breast tumors.
Royal College of General Practitioners: Oral contraceptives and health. New York, Pittman, Risk of gallbladder disease: a cohort study of young women attending family planning clinics. J Epidemiol Community Health ; — Oral contraceptives and other risk factors for gallbladder disease. Clin Pharmacol Ther ; — Comparison of effects of different combined oral-contraceptive formulations on carbohydrate and lipid metabolism. Wynn V. Effect of progesterone and progestins on carbohydrate metabolism.
In Progesterone and Progestin. New York, Raven Press, pp. Oral glucose tolerance and the potency of oral contraceptive progestogens. J Chronic Dis ; — Fisch IR, Frank J.
Oral contraceptives and blood pressure. Laragh AJ. Oral contraceptive induced hypertension—nine years later. In Pharmacology of Steroid Contraceptive Drugs. Garattini S, Berendes HW. Stockley I. Interactions with oral contraceptives.
J Pharm ; — Functional ovarian cysts and oral contraceptives: negative association confirmed surgically. Oral contraceptives and reduced risk of benign breast disease. The noncontraceptive health benefits from oral contraceptive use. Fam Plann Perspect ; — Making Choices: Evaluating the health risks and benefits of birth control methods. Breast Cancer in relation to early use of oral contraceptives ; — A case-controlled study of oral contraceptive use and breast cancer.
JNCI ; — Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Cancer ; — Oral contraceptive use in breast cancer in young women. Oral contraceptives and premenopausal breast cancer in nulliparous women. Contraception ; — Breast cancer before age 45 and oral contraceptive use: New Findings.
Epidemiol ; — Schlesselman JJ. Cancer of the breast and reproductive tract in relation to use of oral contraceptives. Oral contraceptives and breast cancer: latest findings in a large cohort study. Oral contraceptives and breast cancer. Godsland, I et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. Kloosterboer, HJ et al.
Selectivity in progesterone and androgen receptor binding of progestogens used in oral contraception. Contraception, ; — Van der Vies, J and de Visser, J. Endocrinological studies with desogestrel. Data on file, Organon Inc. Fotherby, K. Oral contraceptives, lipids and cardiovascular diseases. Contraception, ; Vol. Lawrence, DM et al. Reduced sex hormone binding globulin and derived free testosterone levels in women with severe acne.
Clinical Endocrinology, ; — Cullberg, G et al. Effects of a low-dose desogestrel-ethinyl estradiol combination on hirsutism, androgens and sex hormone binding globulin in women with a polycystic ovary syndrome. Acta Obstet Gynecol Scand, ; — Jung-Hoffmann, C and Kuhl, H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone.
AJOG, ; — Hammond, G et al. Serum steroid binding protein concentrations, distribution of progestogens, and bioavailability of testosterone during treatment with contraceptives containing desogestrel or levonorgestrel. Palatsi, R et al. Serum total and unbound testosterone and sex hormone binding globulin SHBG in female acne patients treated with two different oral contraceptives. Acta Derm Venereol, ; — Oral contraceptives and nonfatal vascular disease. Obstet Gynecol ; —4.
Mortality among oral contraceptive users. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet, ; — Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. Br Med J, ; — Oral contraceptives induce lamotrigine metabolism: evidence from a doubleblind, placebo-controlled trial.
Epilepsia ;48 3 This product like all oral contraceptives is intended to prevent pregnancy. For most women, oral contraceptives are also free of serious or unpleasant side effects. However, forgetting to take pills considerably increases the chances of pregnancy.
For the majority of women, oral contraceptives can be taken safely. But there are some women who are at high risk of developing certain serious diseases that can be life-threatening or may cause temporary or permanent disability. The risks associated with taking oral contraceptives increase significantly if you:.
Although cardiovascular disease risks may be increased with oral contraceptive use after age 40 in healthy, non-smoking women even with the newer low-dose formulations , there are also greater potential health risks associated with pregnancy in older women.
You should not take the pill if you suspect you are pregnant or have unexplained vaginal bleeding. Women who use oral contraceptives are strongly advised not to smoke. Most side effects of the pill are not serious. The most common such effects are nausea, vomiting, bleeding between menstrual periods, weight gain, breast tenderness, headache, and difficulty wearing contact lenses. These side effects, especially nausea and vomiting, may subside within the first three months of use.
The serious side effects of the pill occur very infrequently, especially if you are in good health and are young. However, you should know that the following medical conditions have been associated with or made worse by the pill:. The symptoms associated with these serious side effects are discussed in the detailed leaflet given to you with your supply of pills. Notify your doctor or healthcare provider if you notice any unusual physical disturbances while taking the pill.
In addition, drugs such as rifampin, as well as some anticonvulsants and some antibiotics may decrease oral contraceptive effectiveness. There is conflict among studies regarding breast cancer and oral contraceptive use. Some studies have reported an increase in the risk of developing breast cancer, particularly at a younger age. This increased risk appears to be related to duration of use. The majority of studies have found no overall increase in the risk of developing breast cancer.
Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives.
There is insufficient evidence to rule out the possibility that pills may cause such cancers. Taking the pill provides some important non-contraceptive benefits. These include less painful menstruation, less menstrual blood loss and anemia, fewer pelvic infections, and fewer cancers of the ovary and the lining of the uterus. Be sure to discuss any medical condition you may have with your doctor or healthcare provider.
Your doctor or healthcare provider will take a medical and family history before prescribing oral contraceptives and will examine you. The physical examination may be delayed to another time if you request it and your doctor or healthcare provider believes that it is a good medical practice to postpone it. You should be reexamined at least once a year while taking oral contraceptives. The detailed patient information leaflet gives you further information which you should read and discuss with your doctor or healthcare provider.
It does not protect against transmission of HIV AIDS and other sexually transmitted diseases such as chlamydia, genital herpes, genital warts, gonorrhea, hepatitis B, and syphilis. You have a choice of which day to start taking your first pack of pills.
0コメント